LNC Therapeutics has raised €6.5m in a Series C funding round as the company announces a new chief science officer and steps up an ‘ambitious’ microbiota-orientated strategy that it hopes will drive an IPO by the end of 2019.
In the same category
Seventure Partners : Une croissance continue dans le secteur du microbiome en 2021 qui va se...
Mar 15, 2022
more +